Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia

Next Previous
X
Search
Trial Profile

A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trimodulin (Primary)
  • Indications Community-acquired pneumonia; COVID 2019 infections; COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms TRICOVID
  • Sponsors Biotest AG; Biotest Pharmaceuticals

    • Most Recent Events

    • 03 Apr 2024 This trial has been Discontinued in Spain, according to European Clinical Trials Database.
    • 12 Dec 2023 According to a Biotest Pharmaceuticals media release, trial has now been opened for enrolment of patients with CAP caused by any type of pathogen.
    • 12 Dec 2023 According to a Biotest Pharmaceuticals media release, first hospitalized patient with Community-Acquired Pneumonia (CAP) has been treated .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top